

1600

RECEIVE

PATENT: 933-154P

TECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

VELI-MATTI LEHTOLA et al.

Application No.:

09/486,971

Group:

1614

Filed:

APRIL 11, 2000

Examiner: UNASSIGNED

For:

PHARMACEUTICAL PREPARATION COMPRISING

CLODRONATE AS ACTIVE INGREDIENT AND SILICIFIED

MICROCRYSTALLINE CELLULOSE AS EXCIPIENT

### REQUEST FOR A CORRECTED OFFICIAL FILING RECEIPT

JUL 24 2000

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Attached hereto is the Official Filing Receipt in connection with the above-identified application.

### THE FOLLOWING CORRECTION IS RESPECTFULLY REQUESTED:

#### FILING DATE--

Change From:

"05/19/2000"

To:

--4/11/2000--

It is respectfully requested that the United States Patent and Trademark Office forward a new Filing Receipt showing the correction to the undersigned attorney as listed on the enclosed photocopy of our postcard.

The correction is due to an error by the United States Patent and Trademark Office, therefore no fee is due.

If necessary, the commissioner is hereby authorized in this, concurrent, and future replies, to charge payment of credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. 1.16 or under 37 C.F.R. 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

BY:

Gerald M. Murphy Reg. No. 28,977

P.O. Box 747 Falls Church, VA 22040-0747

Attachment GMM/MWMrem (703)205-8000

# FILING RECEIPT \*OC000000005154139\*



# UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: ASSISTANT SECRETARY AND COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/486,971	05/19/2000	1614	1100	933-154PCT		10	2

10 RECEÎVED

2292 BIRCH STEWART KOLASCH & BIRCH P O BOX 747 FALLS CHURCH, VA 22040-0747

AUG 18 2000

**TECH CENTER 1600/2900** 

Date Mailed: 06/06/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

VELI-MATTI LEHTOLA, TURKU, FINLAND; EEVA-MARIA RANTALA, PAIMIO, FINLAND; PERTTI RANTALA, LITTOINEN, FINLAND;

#### **Continuing Data as Claimed by Applicant**

THIS APPLICATION IS A 371 OF PCT/FI98/00735 09/18/1998

#### Foreign Applications

FINLAND 973733 09/19/1997

If Required, Foreign Filing License Granted 06/02/2000

JUN 3 3 2070

**Title** 

PHARMACEUTICAL PREPARATION COMPRISING CLODRONATE AND ACTIVE INGREDIENT AS SILICIFIED MICROCRYSTALLINE CELLULOSE AS EXCIPIENT

**Preliminary Class** 

514

Data entry by: BARRETO, NGA

Team: OIPE

Date: 06/06/2000



# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

#### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

Receipt is hereby acknowledged of the papers filed as indicated in connection with the above identified case. COMMISSIONER OF PATENTS AND TRADEMARKS  Due Date:  Handcarry:	Letter to Official Draftsman  Drawings Sheets Formal Informat TRADETINK  Completion of Filing Requirements, PCT/DO/EO/905 or PTO-1533 and Executed Declaration  Priority Document(s) / Cover Letter, No. Doc.  Amendment: Transmit Ltr Large Entity Small Entity  Response Information Discl Stmnt. PTO-1449(s) PREES: Letter: Charles Appeal  Discue Fee Transmittal  FEES: Charles Appeal  Other:	SHIP OF ALL SHIP O
Receipt is hereby acknowledged of the papers filed as indicated in connection with the above identified case. COMMISSIONER OF PATENTS AND TRADEMARKS  Due Date: 5 - 6 - 10	Disconnent / Cover Letter  Completion of Filing Requirements, Propagation of Priority Document(s) / Cover Letter, No. Doc.  Transmit Lir Large Entity Small Entity  Response Information Disci Stmnt. PTO-1449(s)  Notice of Appeal Issue Fee Transmittal Cother:  Other:	MUM P TOLA CE MILLA CE